Web Desc
Alzheimer's Disease Beyond Abeta
Organizer(s): JoAnne McLaurin and Tony Wyss-Coray
Date: January 10 - 15, 2010
Location: Copper Mountain Resort, Copper Mountain, CO, USA
Sponsored by Takeda Pharmaceutical Company Limited
Summary of Meeting:
By 2010 many of the clinical trials presently underway targeting Abeta will have been completed or far enough along the pathway that we will have a better understanding of the benefit and limitations of this approach. This leads us to consider what are the next targets that will need to be addressed to fully treat and prevent Alzheimer’s disease. The objective of this meeting is therefore to stimulate and promote a discussion beyond Abeta as a key factor and therapeutic target in Alzheimer's Disease. This objective will be equally important whether therapeutic approaches targeting Abeta are successful or not, to either complement and expand successful Abeta therapies or to initiate a paradigm shift. In particular, we would like to discuss the generation of alternative models to study Alzheimer's Disease, and highlight several exciting areas of research including the role of synaptic dysfunction, neuronal regeneration, the immune system, and protein degradation in Alzheimer's Disease.
Scholarship Deadline: September 15 2009
Discounted Abstract Deadline: September 15 2009
Abstract Deadline: October 13 2009
Discounted Registration Deadline: November 10 2009
We gratefully acknowledge additional support for this conference from:
AlzheimerMedivation, Inc.Takeda Pharmaceutical Company Limited
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Avid Radiopharmaceuticals, Inc.

Genentech, Inc.

Lilly UK

Pfizer Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
ACS PublicationsGerontological Society of America
We gratefully acknowledge the generous grant for this conference provided by:

National Institute on Aging (NIA)
Grant No. 1R13AG034733-01
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, January 10 | 3:00PM - 7:30PM
Registration
Room: Kokopelli's


Sunday, January 10 | 6:30PM - 7:30PM
Refreshments
Room: Kokopelli's


Sunday, January 10 | 7:30PM - 8:30PM
Keynote Address I
Room: Big Horn B

Speaker 1 of 2
* JoAnne McLaurin, University of Toronto, Canada

Sunday, January 10 | 7:30PM - 8:30PM
Keynote Address I
Room: Big Horn B

Speaker 2 of 2
Dora Games, Neotope Biosciences, USA
Issues and Advances in the Development of Immunotherapeutic Approaches for Alzheimer's Disease

Sunday, January 10 | 8:30PM - 9:30PM
Keynote Address II
Room: Big Horn B

Speaker 1 of 2
* Tony Wyss-Coray, Stanford University School of Medicine, USA

Sunday, January 10 | 8:30PM - 9:30PM
Keynote Address II
Room: Big Horn B

Speaker 2 of 2
Lennart Mucke, Gladstone Institutes and University of California, San Francisco, USA
Strategies to Block Alzheimer's Disease-Associated Neuronal Dysfunction

Monday, January 11 | 7:00AM - 8:00AM
Breakfast
Room: Kokopelli's


Monday, January 11 | 8:00AM - 11:00AM
Remodeling Alzheimer's Disease: An Academic Perspective
Room: Big Horn B
Many treatment strategies have been developed for Alzheimer's disease in animal models without adequate translation to humans. Where are the deficiencies in our models? What can be changed/enhanced for more direct translation to humans?
Speaker 1 of 5
* Lennart Mucke, Gladstone Institutes and University of California, San Francisco, USA

Monday, January 11 | 8:00AM - 11:00AM
Remodeling Alzheimer's Disease: An Academic Perspective
Room: Big Horn B
Many treatment strategies have been developed for Alzheimer's disease in animal models without adequate translation to humans. Where are the deficiencies in our models? What can be changed/enhanced for more direct translation to humans?
Speaker 2 of 5
Todd Eliot Golde, Mayo Clinic Jacksonville, USA
Preclincial Studies of Alzheimer's Disease and the Treatment versus Prevention Paradox

Monday, January 11 | 8:00AM - 11:00AM
Remodeling Alzheimer's Disease: An Academic Perspective
Room: Big Horn B
Many treatment strategies have been developed for Alzheimer's disease in animal models without adequate translation to humans. Where are the deficiencies in our models? What can be changed/enhanced for more direct translation to humans?
Speaker 3 of 5
Bart De Strooper, University College London, UK
Dysregulation of the microRNA network in sporadic Alzheimer's disease

Monday, January 11 | 8:00AM - 11:00AM
Remodeling Alzheimer's Disease: An Academic Perspective
Room: Big Horn B
Many treatment strategies have been developed for Alzheimer's disease in animal models without adequate translation to humans. Where are the deficiencies in our models? What can be changed/enhanced for more direct translation to humans?
Speaker 4 of 5
Roxana Octavia Carare, University of Southampton, UK
Perivascular Drainage of Abeta and the Pathology of CAA

Monday, January 11 | 8:00AM - 11:00AM
Remodeling Alzheimer's Disease: An Academic Perspective
Room: Big Horn B
Many treatment strategies have been developed for Alzheimer's disease in animal models without adequate translation to humans. Where are the deficiencies in our models? What can be changed/enhanced for more direct translation to humans?
Speaker 5 of 5
William J. Jagust, University of California, Berkeley, USA
Structural and Neurochemical Changes within the CNS during Aging and AD in Aging and AD

Monday, January 11 | 9:20AM - 9:40AM
Coffee Break
Room: Kokopelli's


Monday, January 11 | 11:00AM - 1:00PM
Poster Setup
Room: Big Horn C


Monday, January 11 | 11:00AM - 11:00AM
On Own for Lunch and Recreation


Monday, January 11 | 1:00PM - 10:00PM
Poster Viewing
Room: Big Horn C


Monday, January 11 | 4:30PM - 5:00PM
Coffee Available
Room: Kokopelli's


Monday, January 11 | 5:00PM - 7:00PM
Remodeling Alzheimer's Disease II: An Industry Perspective
Room: Big Horn B
Which neurotransmitter systems are disturbed in Alzheimer's Disease early on. How does their disruption contribute to disease and are they potential therapeutic targets.
Speaker 1 of 4
* Dora Games, Neotope Biosciences, USA

Monday, January 11 | 5:00PM - 7:00PM
Remodeling Alzheimer's Disease II: An Industry Perspective
Room: Big Horn B
Which neurotransmitter systems are disturbed in Alzheimer's Disease early on. How does their disruption contribute to disease and are they potential therapeutic targets.
Speaker 2 of 4
Marc Tessier-Lavigne, Stanford University, USA
APP-DR6 Signaling in Axon Development, Regeneration, and Degeneration

Monday, January 11 | 5:00PM - 7:00PM
Remodeling Alzheimer's Disease II: An Industry Perspective
Room: Big Horn B
Which neurotransmitter systems are disturbed in Alzheimer's Disease early on. How does their disruption contribute to disease and are they potential therapeutic targets.
Speaker 3 of 4
Menelas N. Pangalos, AstraZeneca, UK
Beyond Abeta Based Therapies: Developing Novel Modulators of Neurotransmission

Monday, January 11 | 5:00PM - 7:00PM
Remodeling Alzheimer's Disease II: An Industry Perspective
Room: Big Horn B
Which neurotransmitter systems are disturbed in Alzheimer's Disease early on. How does their disruption contribute to disease and are they potential therapeutic targets.
Speaker 4 of 4
Amie L. Phinney, Solvay Pharmaceuticals, Netherlands
Short Talk: The Impact of Biomarkers on Alzheimer’s Disease Drug Discovery

Monday, January 11 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Kokopelli's


Monday, January 11 | 7:30PM - 10:00PM
Poster Session 1
Room: Big Horn C


Tuesday, January 12 | 7:00AM - 8:00AM
Breakfast
Room: Kokopelli's


Tuesday, January 12 | 8:00AM - 11:00AM
Alzheimer's and Synaptic/Neuronal Disfunction
Room: Big Horn B
How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present.
Speaker 1 of 6
* William E. Van Nostrand, Stony Brook University, USA

Tuesday, January 12 | 8:00AM - 11:00AM
Alzheimer's and Synaptic/Neuronal Disfunction
Room: Big Horn B
How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present.
Speaker 2 of 6
Sheena Josselyn, Hospital for Sick Children, Canada
Cognitive Deficits in a Mouse Model of Alzheimer's Disease: The Role of CREB

Tuesday, January 12 | 8:00AM - 11:00AM
Alzheimer's and Synaptic/Neuronal Disfunction
Room: Big Horn B
How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present.
Speaker 3 of 6
Ottavio Arancio, Columbia University Medical Center, USA
Amyloid-beta: From Physiology to Pathology

Tuesday, January 12 | 8:00AM - 11:00AM
Alzheimer's and Synaptic/Neuronal Disfunction
Room: Big Horn B
How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present.
Speaker 4 of 6
Steffany A.L. Bennett, University of Ottawa, Canada
Phospholipid Mediators of Synaptic Dysfunction

Tuesday, January 12 | 8:00AM - 11:00AM
Alzheimer's and Synaptic/Neuronal Disfunction
Room: Big Horn B
How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present.
Speaker 5 of 6
Guojun Bu, Mayo Clinic, USA
ApoE and its Receptor in Brain Lipid Metabolism in AD

Tuesday, January 12 | 8:00AM - 11:00AM
Alzheimer's and Synaptic/Neuronal Disfunction
Room: Big Horn B
How are synapses affected in Alzheimer's Disease, do entire neurons disappear or individual synapses, or are synapses simply misfunctioning and still present.
Speaker 6 of 6
Cynthia A. Massaad, Baylor College of Medicine, USA
Short Talk: Mitochondrial Free Radicals Play a Critical Role in Alzheimer’s Disease-Related Blood Flow and Axonal Transport Deficits Pathology

Tuesday, January 12 | 9:20AM - 9:40AM
Coffee Break
Room: Kokopelli's


Tuesday, January 12 | 11:00AM - 11:00AM
On Own for Lunch and Recreation


Tuesday, January 12 | 11:00AM - 1:00PM
Poster Setup
Room: Big Horn C


Tuesday, January 12 | 1:00PM - 10:00PM
Poster Viewing
Room: Big Horn C


Tuesday, January 12 | 4:30PM - 5:00PM
Coffee Available
Room: Kokopelli's


Tuesday, January 12 | 5:00PM - 7:00PM
Alzheimer's Disease and Neuronal Regeneration
Room: Big Horn B
Compounds are presently being developed that target neurons for enhancement of function and/or regeneration. What is the role of stem cells, neurogenesis and repair mechanisms to improvement of cognitive function in Alzheimer's Disease?
Speaker 1 of 5
* Bruce T. Lamb, Indiana University School of Medicine, USA

Tuesday, January 12 | 5:00PM - 7:00PM
Alzheimer's Disease and Neuronal Regeneration
Room: Big Horn B
Compounds are presently being developed that target neurons for enhancement of function and/or regeneration. What is the role of stem cells, neurogenesis and repair mechanisms to improvement of cognitive function in Alzheimer's Disease?
Speaker 2 of 5
Frank Longo, Stanford School of Medicine, USA
Small Molecule p75 Receptor Ligands Inhibit Abeta-Induced Degeneration, Synaptic Dysfunction and Cognitive Loss

Tuesday, January 12 | 5:00PM - 7:00PM
Alzheimer's Disease and Neuronal Regeneration
Room: Big Horn B
Compounds are presently being developed that target neurons for enhancement of function and/or regeneration. What is the role of stem cells, neurogenesis and repair mechanisms to improvement of cognitive function in Alzheimer's Disease?
Speaker 3 of 5
Daniel A. Peterson, Rosalind Franklin University, Chicago Medical School, USA
The Contribution of Neurogenesis in Repairing the Aging Brain

Tuesday, January 12 | 5:00PM - 7:00PM
Alzheimer's Disease and Neuronal Regeneration
Room: Big Horn B
Compounds are presently being developed that target neurons for enhancement of function and/or regeneration. What is the role of stem cells, neurogenesis and repair mechanisms to improvement of cognitive function in Alzheimer's Disease?
Speaker 4 of 5
Stephen M. Strittmatter, Yale University, USA
Beyond (Downstream of) Abeta: NgR and PrP

Tuesday, January 12 | 5:00PM - 7:00PM
Alzheimer's Disease and Neuronal Regeneration
Room: Big Horn B
Compounds are presently being developed that target neurons for enhancement of function and/or regeneration. What is the role of stem cells, neurogenesis and repair mechanisms to improvement of cognitive function in Alzheimer's Disease?
Speaker 5 of 5
Patrick A. Lewis, University of Reading, UK
Short Talk: Investigating Lewy Body Disease with Human Neuronal Cells

Tuesday, January 12 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Kokopelli's


Tuesday, January 12 | 7:30PM - 10:00PM
Poster Session 2
Room: Big Horn C


Wednesday, January 13 | 7:00AM - 8:00AM
Breakfast
Room: Kokopelli's


Wednesday, January 13 | 8:00AM - 11:00AM
Alzheimer's and the Immune System
Room: Big Horn B
What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta.
Speaker 1 of 6
* Andrea J. Tenner, University of California, Irvine, USA

Wednesday, January 13 | 8:00AM - 11:00AM
Alzheimer's and the Immune System
Room: Big Horn B
What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta.
Speaker 2 of 6
Richard M. Ransohoff, Third Rock Ventures, USA
Microglia, Monocytes and Macrophages

Wednesday, January 13 | 8:00AM - 11:00AM
Alzheimer's and the Immune System
Room: Big Horn B
What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta.
Speaker 3 of 6
Terrence Town, Cedars-Sinai University of California Los Angeles, USA
Inflammation and Innate Immunity in Alzheimer's Disease

Wednesday, January 13 | 8:00AM - 11:00AM
Alzheimer's and the Immune System
Room: Big Horn B
What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta.
Speaker 4 of 6
Josef Priller, Charité – Universitätsmedizin Berlin, Germany
Bone Marrow-Derived Cells in Models of Alzheimer's Disease

Wednesday, January 13 | 8:00AM - 11:00AM
Alzheimer's and the Immune System
Room: Big Horn B
What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta.
Speaker 5 of 6
Joseph El Khoury, Massachusetts General Hospital, USA
Chemokines and Mononuclear Phagocytes recruited in AD

Wednesday, January 13 | 8:00AM - 11:00AM
Alzheimer's and the Immune System
Room: Big Horn B
What is the role of the immune system in Alzheimer's Disease? Are immune processes overactivated (inflammation) or are they deficient? Are peripheral cells recruited to the CNS and if so, what are they doing? Are peripheral immune responses changed in Alzheimer's Disease and what is their role in the disease? What is the role of microglia and what subsets of this cell type are in the brain (dendritic type CD11c, newly recruited cells, perivascular macrophages). Autoantibodies against Abeta.
Speaker 6 of 6
Marie E. Benoit, University of California, Irvine regents, USA
Short Talk: Neuroprotective Pathways Stimulated by the Complement Protein C1q in Neurons

Wednesday, January 13 | 9:20AM - 9:40AM
Coffee Break
Room: Kokopelli's


Wednesday, January 13 | 11:00AM - 1:00PM
Poster Setup
Room: Big Horn C


Wednesday, January 13 | 11:00AM - 11:00AM
On Own for Lunch and Recreation


Wednesday, January 13 | 1:00PM - 10:00PM
Poster Viewing
Room: Big Horn C


Wednesday, January 13 | 4:30PM - 5:00PM
Coffee Available
Room: Kokopelli's


Wednesday, January 13 | 5:00PM - 7:00PM
Alzheimer's and Protein Degradation
Room: Big Horn B
What is the role of the lysosomal system, are changes early or late in disease? How do lysosomal abnormalities relate to autophagy? Proteasomal dysfunction and neurodegeneration. How does this all affect Abeta generation and tau accumulation?
Speaker 1 of 5
* Terrence Town, Cedars-Sinai University of California Los Angeles, USA

Wednesday, January 13 | 5:00PM - 7:00PM
Alzheimer's and Protein Degradation
Room: Big Horn B
What is the role of the lysosomal system, are changes early or late in disease? How do lysosomal abnormalities relate to autophagy? Proteasomal dysfunction and neurodegeneration. How does this all affect Abeta generation and tau accumulation?
Speaker 2 of 5
Jeffery W. Kelly, The Scripps Research Institute, USA
Proteostasis

Wednesday, January 13 | 5:00PM - 7:00PM
Alzheimer's and Protein Degradation
Room: Big Horn B
What is the role of the lysosomal system, are changes early or late in disease? How do lysosomal abnormalities relate to autophagy? Proteasomal dysfunction and neurodegeneration. How does this all affect Abeta generation and tau accumulation?
Speaker 3 of 5
Kent B. Matlack, Whitehead Institute for Biomedical Research, USA
Using Simple Cells to Model Complex Diseases

Wednesday, January 13 | 5:00PM - 7:00PM
Alzheimer's and Protein Degradation
Room: Big Horn B
What is the role of the lysosomal system, are changes early or late in disease? How do lysosomal abnormalities relate to autophagy? Proteasomal dysfunction and neurodegeneration. How does this all affect Abeta generation and tau accumulation?
Speaker 4 of 5
Zhenyu Yue, Mount Sinai Medical Center, USA
Autophagy: Cell Self-Eating in Alzheimer's Disease

Wednesday, January 13 | 5:00PM - 7:00PM
Alzheimer's and Protein Degradation
Room: Big Horn B
What is the role of the lysosomal system, are changes early or late in disease? How do lysosomal abnormalities relate to autophagy? Proteasomal dysfunction and neurodegeneration. How does this all affect Abeta generation and tau accumulation?
Speaker 5 of 5
Gizem Donmez, Tufts University School of Medicine, USA
Short Talk: SIRT1 Suppresses Alzheimer´s Disease by Activating the Alpha Secretase Gene ADAM10 in APPswe, PSEN1dE9 Mouse Model

Wednesday, January 13 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Kokopelli's


Wednesday, January 13 | 7:30PM - 10:00PM
Poster Session 3
Room: Big Horn C


Thursday, January 14 | 7:00AM - 8:00AM
Breakfast
Room: Kokopelli's


Thursday, January 14 | 8:00AM - 11:00AM
Alzheimer's Disease and Diagnostics
Room: Big Horn B
Are we imaging the appropriate targets in Alzheimer's Disease? How can the techniques be improved? What is the meaning of brain volume changes in response to treatment paradigms and cognition in general? Can biomarkers lead us to novel imaging targets?
Speaker 1 of 5
Daniel M. Skovronsky, Eli Lilly and Company, USA
PET Radiopharmaceuticals for Diagnosis of Dementias

Thursday, January 14 | 8:00AM - 11:00AM
Alzheimer's Disease and Diagnostics
Room: Big Horn B
Are we imaging the appropriate targets in Alzheimer's Disease? How can the techniques be improved? What is the meaning of brain volume changes in response to treatment paradigms and cognition in general? Can biomarkers lead us to novel imaging targets?
Speaker 2 of 5
Holly Soares, Bristol-Myers Squibb, USA
Multiplex Panels as Diagnostic Tools in Alzheimer’s Disease

Thursday, January 14 | 8:00AM - 11:00AM
Alzheimer's Disease and Diagnostics
Room: Big Horn B
Are we imaging the appropriate targets in Alzheimer's Disease? How can the techniques be improved? What is the meaning of brain volume changes in response to treatment paradigms and cognition in general? Can biomarkers lead us to novel imaging targets?
Speaker 3 of 5
Neill Graff-Radford, Mayo Clinic, USA
What have we learned from plasma Abeta?

Thursday, January 14 | 8:00AM - 11:00AM
Alzheimer's Disease and Diagnostics
Room: Big Horn B
Are we imaging the appropriate targets in Alzheimer's Disease? How can the techniques be improved? What is the meaning of brain volume changes in response to treatment paradigms and cognition in general? Can biomarkers lead us to novel imaging targets?
Speaker 4 of 5
* Tony Wyss-Coray, Stanford University School of Medicine, USA
The Plasma Communicome of Normal Aging and Dementia

Thursday, January 14 | 8:00AM - 11:00AM
Alzheimer's Disease and Diagnostics
Room: Big Horn B
Are we imaging the appropriate targets in Alzheimer's Disease? How can the techniques be improved? What is the meaning of brain volume changes in response to treatment paradigms and cognition in general? Can biomarkers lead us to novel imaging targets?
Speaker 5 of 5
Alice M. Wyrwicz, NorthShore University HealthSystem, USA
Short Talk: Diffusion Tensor Imaging as a Potential Biomarker of Dendritic Alterations in Mouse Models of AD

Thursday, January 14 | 9:20AM - 9:40AM
Coffee Break
Room: Kokopelli's


Thursday, January 14 | 11:00AM - 11:00AM
On Own for Lunch and Recreation


Thursday, January 14 | 4:30PM - 5:00PM
Coffee Available
Room: Kokopelli's


Thursday, January 14 | 5:00PM - 7:00PM
Alzheimer's Disease and Therapeutics
Room: Big Horn B
If anti-amyloid/tau therapies work or don't, what are the lead-on areas that will need to be addressed to deal with cognitive function in Alzheimer's Disease. Novel targets or approaches. What role does CAA play in both development and delivery drugs?
Speaker 1 of 4
Kullervo Hynynen, Sunnybrook Health Sciences Centre, Canada
MRI Guided Ultrasound Delivery of Drugs to the CNS

Thursday, January 14 | 5:00PM - 7:00PM
Alzheimer's Disease and Therapeutics
Room: Big Horn B
If anti-amyloid/tau therapies work or don't, what are the lead-on areas that will need to be addressed to deal with cognitive function in Alzheimer's Disease. Novel targets or approaches. What role does CAA play in both development and delivery drugs?
Speaker 2 of 4
Valerie Cullen, Link Medicine Corp, USA
A New Therapeutic Strategy for Neurodegeneration

Thursday, January 14 | 5:00PM - 7:00PM
Alzheimer's Disease and Therapeutics
Room: Big Horn B
If anti-amyloid/tau therapies work or don't, what are the lead-on areas that will need to be addressed to deal with cognitive function in Alzheimer's Disease. Novel targets or approaches. What role does CAA play in both development and delivery drugs?
Speaker 3 of 4
* JoAnne McLaurin, University of Toronto, Canada
Small Molecule Therapy for Alzheimer's Disease

Thursday, January 14 | 5:00PM - 7:00PM
Alzheimer's Disease and Therapeutics
Room: Big Horn B
If anti-amyloid/tau therapies work or don't, what are the lead-on areas that will need to be addressed to deal with cognitive function in Alzheimer's Disease. Novel targets or approaches. What role does CAA play in both development and delivery drugs?
Speaker 4 of 4
Linda J. Van Eldik, University of Kentucky, USA
Short Talk: Targeting Glia-Neuron Interactions that Result in Synaptic Dysfunction as a Drug Discovery Strategy for Alzheimer’s Disease

Thursday, January 14 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Kokopelli's


Thursday, January 14 | 8:00PM - 11:00PM
Entertainment
Room: Big Horn C


Thursday, January 14 | 8:00PM - 11:00PM
Cash Bar
Room: Big Horn C


Friday, January 15 | 10:25AM - 10:25AM
Departure


*Session Chair.